Similar Articles
631 Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
632 Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function
633 Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
634 Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report
635 Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
636 Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
637 Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma
638 Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report
639 Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
640 Apatinib as an alternative therapy for advanced hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA